Key Points
- Director Frank Morich bought 15,000 shares at $0.94 for $14,100, doubling his reported holdings to 30,000 shares. He had also purchased 15,000 shares four days earlier at $1.00.
- Perspective Therapeutics reported a quarterly loss of $0.27 per share, missing estimates, while revenue of $0.02 million was below expectations. The stock opened at $0.86, near its 52-week low of $0.78 and below its 50- and 200-day moving averages.
- Analysts have a consensus “Moderate Buy” rating and an average price target of $10.10, although several firms have recently lowered their targets.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) Director Frank Morich bought 15,000 shares of Perspective Therapeutics stock in a transaction dated Monday, November 16th. The stock was purchased at an average cost of $0.94 per share, with a total value of $14,100.00. Following the completion of the acquisition, the director directly owned 30,000 shares in the company, valued at approximately $28,200. The trade was a 100.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Frank Morich also recently made the following trade(s):
- On Thursday, November 12th, Frank Morich acquired 15,000 shares of Perspective Therapeutics stock. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $15,000.00.
Perspective Therapeutics Stock Down 6.9%
CATX opened at $0.86 on Wednesday. The business has a 50 day moving average price of $2.02 and a two-hundred day moving average price of $3.42. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a 52 week low of $0.78 and a 52 week high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The firm had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.06 million. On average, equities research analysts predict that Perspective Therapeutics, Inc. will post -1.01 EPS for the current fiscal year.
Perspective Therapeutics News Roundup
These are some of the CATX news items that stood out recently:
- Positive Sentiment: Directors Frank Morich, Lori Woods, and Robert Williamson bought shares on November 12, together acquiring about 63,600 shares at prices of $0.84–$1.00. Morich then bought another 15,000 shares on November 16 at $0.94, bringing his reported ownership to 30,000 shares. The cluster of purchases may signal confidence from company insiders, though the dollar amounts were relatively small. Insider purchase report
- Negative Sentiment: CATX remains under pressure amid weak financial results: the company recently reported a quarterly loss per share wider than analysts expected and revenue below consensus. The stock is also trading well below its 50- and 200-day moving averages, near its 12-month low, suggesting ongoing investor concerns despite insider buying.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on CATX shares. Piper Sandler cut their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Bank of America decreased their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, August 14th. Wedbush reaffirmed an "outperform" rating and set a $7.00 price target (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. BTIG Research reiterated a "buy" rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.10.
View Our Latest Stock Report on CATX
Institutional Investors Weigh In On Perspective Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Provenance Wealth Advisors LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter worth approximately $44,000. Auctus Advisors LLC raised its holdings in Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company's stock worth $103,000 after purchasing an additional 17,015 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Perspective Therapeutics by 53.1% during the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company's stock worth $168,000 after purchasing an additional 21,150 shares during the last quarter. Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 127.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company's stock worth $225,000 after purchasing an additional 37,000 shares during the last quarter. Finally, Quantinno Capital Management LP purchased a new stake in Perspective Therapeutics during the first quarter worth $273,000. Institutional investors and hedge funds own 54.66% of the company's stock.
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Further Reading

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].